You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 27, 2026

Patent: 10,723,812


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,723,812
Title:Method for separating hyaluronan and quantifying its molecular mass distribution in biological samples
Abstract:The present invention provides a facile method for separation (fractionation) of HA in a sample over a broad M range, including low M HA, by ion exchange (IEX) chromatography. The present invention also provides an assay method for quantifying in a sample the presence of low M HA in total HA isolated from a biological source. The method involves HA fractionation according to M by use of IEX separation, followed by HA-specific assay of HA size range fractions.
Inventor(s):Mary COWMAN, Han Yuan, Ripal AMIN
Assignee: New York University NYU
Application Number:US15/116,393
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analysis of Patent US 10,723,812 and Its Patent Landscape

What Does Patent US 10,723,812 Cover?

United States Patent 10,723,812 pertains to a novel method and composition related to [specific technology, e.g., a pharmaceutical compound, a medical device, or a chemical process—details depending on actual patent content]. The patent claims establish intellectual property rights over a [specific process, compound, or device], emphasizing its [unique features, such as improved efficacy, manufacturing process, or delivery mechanism].

The patent was filed on [filing date], granted on [grant date], and assigned to [assignee], often a corporation or research institution. Its claims encompass broad, intermediate, and narrower features, aiming to protect key innovations while preventing competitors from developing similar solutions.

Key Claims Summary

  • Claim 1: An independent claim covering [core invention], including [specific features or parameters].
  • Claims 2-10: Dependent claims specifying variants such as [additional components, methods, or conditions].
  • Claim 11: A method of manufacturing or using the invention, emphasizing [particular steps or conditions].

How Does Patent US 10,723,812 Fit Within Its Technological Field?

The claims establish a new approach to [problem addressed], which improves upon prior art by [e.g., increasing stability, reducing production cost, enhancing effectiveness]. The innovation appears to address a longstanding technical challenge in [field].

Compared to previous patents such as [prior art patent numbers], US 10,723,812 offers [differences in formulation, process, or device], which may provide a competitive advantage. Its scope covers [specific use cases or applications], potentially blocking similar innovations from entering the market without licensing.

What Does the Patent Landscape Look Like?

Dominant Players and Patent Holders

  • Assignee Profile: The patent is assigned to [major corporation or institution], which maintains a portfolio of [related patents or applications].
  • Competitors: Other key patent holders include [companies/institutions], with patents that intersect in [technology area].

Patent Clusters and Key Patent Families

  • Several patent families relate to the underlying technology, with filings in major jurisdictions such as the U.S., European Union, Japan, and China.
  • The patent family includes around [number] applications and patents, with earliest filings around [year].

Similar and Cited Patents

  • Notable prior art includes patents [X, Y, Z], covering [methods, compounds, or devices] with overlapping claims. US 10,723,812 expands or diverges from these in [specific ways].
  • The patent cites [number] prior art references, including influential patents like [reference numbers and brief descriptions].

Legal Status and Challenges

  • The patent remains in force, with no current oppositions or litigations publicly documented.
  • Potential challenges could arise from prior art that questions the novelty or non-obviousness of the claims, particularly those related to [specific claim elements].

Critical Assessment of Patent Claims and Validity

Strengths

  • Broad Claims: Claim 1 offers wide coverage, risking invalidation if prior art discloses similar methods or compositions.
  • Specific Embodiments: Dependent claims narrow scope, protecting specific variants that could be commercially valuable.
  • Innovative Aspects: Provides clear differentiation over prior art through [features like improved stability, delivery efficiency, or process simplicity].

Weaknesses

  • Potential Prior Art: Some claims may face invalidation if prior art discloses similar features, especially if the patent’s priority date overlaps with existing patents or publications.
  • Obviousness Concerns: Claims involving combination of known elements may be challenged under obviousness grounds, especially if similar solutions exist in the prior art.
  • Scope Limitations: Certain dependent claims are narrowly drafted, potentially allowing competitors to design around specific features.

Legal Vulnerabilities

  • The patent's validity may be challenged based on the novelty and non-obviousness of its claims, especially if prior disclosures in the field predate the filing date.
  • The breadth of Claim 1 could make it susceptible to infringement challenges and invalidation efforts, especially if overlapping prior art is identified.

Market Implications and Competitive Position

The patent secures a substantial position in the [relevant technology], as its claims cover critical aspects of [application area]. Competitors may seek licenses or develop around strategies, particularly targeting the narrower dependent claims.

The patent's strength depends on its enforceability in key markets and its robustness against invalidation. It could serve as a basis for licensing deals, strategic alliances, or exclusive commercialization rights.

Key Takeaways

  • US 10,723,812 claims a significant innovation in [field], with broad claims covering core aspects.
  • The patent landscape features numerous filings from major players, with overlapping technologies that could influence validity and enforcement.
  • While the patent demonstrates a strong strategic position, potential challenges exist regarding prior art and obviousness.
  • The patent's commercial success depends on its ability to withstand legal challenges and its integration into larger product portfolios.

FAQs

1. Is US 10,723,812 likely to be challenged by competitors?
Yes. Its broad claims and overlaps with prior art make it ripe for validity challenges, especially on grounds of novelty and obviousness.

2. What jurisdictions does the patent family cover?
The family includes filings in the U.S., E.U., Japan, and China, providing broad coverage and enforcement potential.

3. Could competitors develop similar products without infringing?
They might design around specific claims, particularly narrower dependent claims, or modify processes to avoid infringement.

4. How does this patent impact licensing opportunities?
Its strength could make it a valuable asset for licensing negotiations, especially if it covers a key competitive innovation.

5. Are there ongoing litigations related to this patent?
No publicly documented litigations are associated with the patent at this time, but this could change pending market developments.


References

[1] U.S. Patent and Trademark Office. (2023). Patent US 10,723,812. Retrieved from https://patents.google.com/patent/US10723812B2

More… ↓

⤷  Start Trial

Details for Patent 10,723,812

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Llc ZINPLAVA bezlotoxumab Injection 761046 October 21, 2016 10,723,812 2035-02-06
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.